Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

NCT06592625 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Untreated Early-stage or Locally Advanced Breast Cancer

Interventions

DRUG: SHR-A1811
DRUG: Adebrelimab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.